Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06134232 · ClinicalTrials.gov registry record · Phase 2

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by Dendreon.

Recruiting
Registry status
Phase 2
Development phase
400
Enrollment target
20
Study locations

NCT06134232 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by Dendreon. The registered enrollment target is 400 participants, roughly in line with the 387-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target. The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06134232, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by Dendreon.

RECRUITING
Registry status
Phase 2
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

  • DRUG Sipuleucel-T Injection

Study Locations (20)

Florida

  • Advanced Urology Institute - Daytona Beach
  • Advanced Urology Institute - Largo
  • Advanced Urology Institute - Ocala
  • Florida Urology Partners - Riverview

California

  • City of Hope - National Medical Center - Duarte
  • Urology Associates of Central California Medical Group - Fresno
  • Unio Health Partners - Genesis Research, LLC - San Diego

Illinois

  • Associated Urological Specialists - Chicago Ridge
  • UroPartners - Glenview
  • Advanced Urology Associates - New Lenox

Indiana

  • Urology of Indiana - Carmel
  • First Urology - Jeffersonville
  • Urologic Specialists of Northwest Indiana - Merrillville

New York

  • Integrated Medical Professionals - North Hills
  • Associated Medical Professionals of NY - Syracuse

Arizona

  • Arizona Urology Specialists - Tuscon

Colorado

  • Colorado Urology - Lakewood

Maryland

  • Chesapeake Urology Research Associates - Towson

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2023-10-02
Est. Completion 2032-06-30
Phase Phase 2

Sponsor

Dendreon

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06134232

The ClinicalTrials.gov registry entry for NCT06134232 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 387-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which Sipuleucel-T Injection is the first listed.

NCT06134232 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06134232 about?

NCT06134232 is a clinical study titled "Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T". A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

What is the current status of trial NCT06134232?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2023-10-02. Estimated completion is 2032-06-30.

What conditions does trial NCT06134232 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).

What interventions are being tested in trial NCT06134232?

The interventions under investigation include: Sipuleucel-T Injection (DRUG).

Who is sponsoring clinical trial NCT06134232?

This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06134232 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.